Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This study aimed to investigate the efficacy and s...

Full description

Bibliographic Details
Main Authors: Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini, Armando Orlandi
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-08-01
Series:Cancer Biology & Medicine
Subjects:
metastatic breast cancer
apatinib
oral vinorelbine
ctdna
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1860

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1860

Similar Items